Literature DB >> 23306845

Acid suppression therapy as a risk factor for Candida esophagitis.

Kyung-Yup Kim1, Jae Young Jang, Jung-Wook Kim, Jae-Jun Shim, Chang Kyun Lee, Seok Ho Dong, Hyo Jong Kim, Byung-Ho Kim, Young Woon Chang.   

Abstract

BACKGROUND/AIM: As the prevalence of reflux esophagitis increases, so does the use of gastric acid suppressants. This study aimed to document the prevalence of Candida esophagitis (CE) at a single Korean university hospital over the last 5 years and to evaluate its risk factors.
METHODS: To investigate the prevalence of CE, we conducted a retrospective analysis of 55,314 individuals who underwent a screening esophagogastroduodenoscopy as part of a health check-up between January 2006 and December 2010 at Kyung Hee University Hospital in Seoul, Korea. A total of 250 patients who were treated for CE between January 2008 and August 2011 and 500 age- and sex-matched non-CE patients were enrolled in this study. The rates of recent gastric acid suppression therapy and other well-known risk factors in the two groups were compared.
RESULTS: The prevalence of CE was 0.35 % and increased each year (linear-by-linear association, P = 0.001). Univariate analysis showed that gastric acid suppression therapy, malignancy, DM and steroid therapy were related to CE. Multivariate analysis also showed that gastric acid suppression therapy (OR 5.11, 95 % CI 2.92-8.93 and P < 0.001), malignancy (OR 18.68, 95 % CI 6.37-54.75 and P < 0.001), DM (OR 2.67, 95 % CI 1.70-4.21 and P < 0.001) and steroids therapy (OR 6.74, 95 % CI 1.37-33.05 and P = 0.019) were related to CE.
CONCLUSIONS: The prevalence of CE in Korea is increasing. Also, our results indicate that acid suppression therapy is a meaningful risk factor for CE.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23306845     DOI: 10.1007/s10620-012-2520-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  Clinical findings and risk factors for Candida esophagitis in outpatients.

Authors:  J A Underwood; J W Williams; R F Keate
Journal:  Dis Esophagus       Date:  2003       Impact factor: 3.429

2.  Candida esophagitis after antibiotic use.

Authors:  B R Thapa; L Kumar
Journal:  Indian J Pediatr       Date:  1989 Mar-Apr       Impact factor: 1.967

3.  Predisposing factors and clinical symptoms in HIV-negative patients with Candida oesophagitis: are they always present?

Authors:  K Mimidis; V Papadopoulos; V Margaritis; K Thomopoulos; A Gatopoulou; V Nikolopoulou; G Kartalis
Journal:  Int J Clin Pract       Date:  2005-02       Impact factor: 2.503

4.  Candida infection of the gastrointestinal tract.

Authors:  P Eras; M J Goldstein; P Sherlock
Journal:  Medicine (Baltimore)       Date:  1972-09       Impact factor: 1.889

5.  Conventional dose of omeprazole alters gastric flora.

Authors:  Y Karmeli; R Stalnikowitz; R Eliakim; G Rahav
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

6.  Esophageal candidiasis as a complication of inhaled corticosteroids.

Authors:  M R Simon; W L Houser; K A Smith; P M Long
Journal:  Ann Allergy Asthma Immunol       Date:  1997-10       Impact factor: 6.347

7.  Oesophageal candidiasis after omeprazole therapy.

Authors:  A J Larner; R Lendrum
Journal:  Gut       Date:  1992-06       Impact factor: 23.059

8.  [The prevalence of esophageal disorders in the subjects examined for health screening].

Authors:  Seung Suk Yoo; Won Hyun Lee; Jong Ha; Sun Pil Choi; Hyun Jin Kim; Tae Hyo Kim; Ok Jae Lee
Journal:  Korean J Gastroenterol       Date:  2007-11

9.  Candida esophagitis: risk factors in non-HIV population in Pakistan.

Authors:  Javed Yakoob; Wasim Jafri; Shahab Abid; Nadeem Jafri; Muhammad Islam; Saeed Hamid; Hasnain A Shah; Akbar S Hussainy
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

10.  Activity inhibition of cytolytic lymphocytes by omeprazole.

Authors:  L Scaringi; P Cornacchione; K Fettucciari; E Rosati; R Rossi; P Marconi; E Capodicasa
Journal:  Scand J Immunol       Date:  1996-09       Impact factor: 3.487

View more
  4 in total

1.  Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report.

Authors:  Kuo-Hsin Chen; Meng-Tzu Weng; Yueh-Hung Chou; Yueh-Feng Lu; Chen-Hsi Hsieh
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

2.  Intractable hiccups caused by esophageal diverticular candidiasis in an immunocompetent adult: a case report.

Authors:  Shinsuke Yahata; Tsuneaki Kenzaka; Saeko Kushida; Hogara Nishisaki; Hozuka Akita
Journal:  Int Med Case Rep J       Date:  2017-02-10

3.  The Correlation of Endoscopic Findings and Clinical Features in Korean Patients with Scrub Typhus: A Cohort Study.

Authors:  Jun Lee; Dong-Min Kim; Na Ra Yun; Young Dae Kim; Chan Guk Park; Man Woo Kim
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

Review 4.  The Phylogeny and Biological Function of Gastric Juice-Microbiological Consequences of Removing Gastric Acid.

Authors:  Tom C Martinsen; Reidar Fossmark; Helge L Waldum
Journal:  Int J Mol Sci       Date:  2019-11-29       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.